Myriad Genetics Strategy and Business Model

Executive Overview

Myriad Genetics is a U.S. molecular diagnostics company that uses genetic and genomic testing to help guide screening, diagnosis, treatment selection, and medication decisions. Founded in 1991 and headquartered in Salt Lake City, Utah, Myriad built its original franchise in hereditary cancer testing and has since broadened into women’s health, mental health, and oncology companion diagnostics. Its core offerings include hereditary cancer risk testing, homologous recombination deficiency testing, tumor profiling, reproductive carrier screening, non-invasive prenatal screening, and GeneSight pharmacogenomic testing for psychiatric medication management.

For FY2024, Myriad reported revenue of #N/A. The business remains heavily U.S.-weighted, with a smaller international presence through direct operations and partners. Strategically, Myriad is not just a lab running one-off tests. Its value proposition depends on clinical evidence, payer coverage, bioinformatics, result interpretation, specialist sales execution, and branded products that fit into physician workflows. That makes Myriad part laboratory company, part evidence-generation platform, and part commercial precision-medicine business. The central strategic challenge is to turn that portfolio breadth, historical testing data, and biopharma relationships into durable growth and stronger profitability in competitive, reimbursement-sensitive markets.

Myriad Genetics at a Glance

Logo
Common name	Myriad Genetics
Full legal name	Myriad Genetics, Inc.
Headquarters	Salt Lake City, Utah, United States
Ownership	Public company
Ticker	MYGN
Exchange	NASDAQ
Market Cap	$441.55M
Revenue (FY2024)	#N/A
Founding / major historical milestones	Founded in 1991; IPO in 1995; built an early leadership position in BRCA-related hereditary cancer testing; 2013 U.S. Supreme Court gene-patent decision reshaped its competitive position; expanded through acquisitions including Assurex Health (2016), Sividon Diagnostics (2016), Counsyl (2018), and Gateway Genomics (2021).
Industry or industries	Molecular diagnostics, genetic testing, precision medicine, women’s health diagnostics, oncology diagnostics
Key products or services	myRisk, myChoice CDx, GeneSight, Foresight Carrier Screen, Prequel Prenatal Screen, Prolaris, EndoPredict, Precise Tumor, Precise Liquid, companion diagnostic and biopharma testing services
Geographic footprint	Primarily United States; additional presence in select international markets through direct operations and partner channels
Business segments as officially reported	One reportable segment as of FY2024; management commonly discusses the business through Oncology, Women’s Health, and Mental Health testing franchises
Company website	https://myriad.com/

1. What Is the Strategy of Myriad Genetics?

The discussion below synthesizes Myriad’s FY2024 public filings, investor materials, and earnings communications through the Playing to Win framework. It is an analytical summary of the company’s stated direction, not a verbatim strategy slide.

1. 1a. What is the winning aspiration of Myriad Genetics?

   Myriad’s winning aspiration is to be a scaled precision-medicine diagnostics company whose tests are embedded in clinical decision-making across several high-value specialties rather than being known only for a legacy hereditary cancer franchise. In practical terms, “winning” means becoming a trusted provider of clinically actionable genetic information in oncology, women’s health, and mental health, while improving growth, profitability, and cash generation. In recent public communications, Myriad has emphasized sustainable revenue growth, margin improvement, and stronger operating discipline more than a single long-term market-share target.

2. 1b. Where does Myriad Genetics play?

   Myriad plays in clinician-ordered molecular diagnostics where clinical utility, reimbursement, and interpretation matter enough to support branded testing. Its core arenas are oncology, women’s health, and mental health. Within those areas, it focuses on tests tied to specialist workflows such as hereditary cancer risk assessment, companion diagnostics, tumor profiling, reproductive carrier screening, prenatal screening, and pharmacogenomics. Geographically, the center of gravity is the United States, with a smaller international business and selected partner-led expansion. It also plays in biopharma services where its assays and evidence base can support drug development and companion diagnostics.

3. 1c. How does Myriad Genetics plan to win?

   Myriad does not appear to be trying to win as the lowest-cost lab. It plans to win by combining clinically validated branded tests, a large historical interpretation base, payer relationships, specialist sales coverage, and workflow integration. In categories such as hereditary cancer, prenatal screening, and pharmacogenomics, that means persuading clinicians and payers that Myriad’s tests are not interchangeable commodities. In oncology, it also aims to differentiate through companion diagnostic relationships and evidence that links its assays to therapy selection. The company’s approach is therefore a mix of clinical differentiation, commercial execution, and reimbursement competence.

4. 1d. What capabilities must Myriad Genetics have in place?

   To execute this strategy, Myriad needs several capabilities that are unusually important in diagnostics: assay development; bioinformatics and variant interpretation; high-quality laboratory operations; regulatory and quality-system discipline; payer contracting and reimbursement appeals; medical affairs and evidence generation; and a specialist commercial organization that can educate physicians and health systems. It also needs business development capabilities for biopharma partnerships, because companion diagnostics can deepen its role in precision oncology.

5. 1e. What management systems does Myriad Genetics require?

   Myriad requires management systems that reinforce quality, reimbursement, and operating leverage. That includes laboratory quality systems under applicable Clinical Laboratory Improvement Amendments and accreditation frameworks; test-level economics and reimbursement analytics; salesforce productivity measurement; disciplined R&D stage-gating; and close monitoring of collections, denials, and cash conversion. Because test adoption depends heavily on evidence and payer access, Myriad also needs management routines that connect medical affairs, market access, commercial teams, and laboratory operations rather than treating them as separate silos.

2. What Are the Current Strategic Initiatives of Myriad Genetics?

As reflected in FY2024 filings and related investor communications, Myriad’s current strategic initiatives appear to center on six practical priorities.

• Expand the oncology franchise. Myriad continues to build around hereditary cancer testing, companion diagnostics, and newer precision-oncology offerings. That includes maintaining leadership in hereditary cancer risk assessment while increasing the strategic importance of products such as myChoice CDx, Prolaris, EndoPredict, and newer tumor-profiling offerings.
• Grow women’s health testing. The company has continued to invest behind reproductive carrier screening and prenatal screening, especially through the Foresight and Prequel brands. This initiative depends on OB/GYN channel penetration, payer coverage, digital ordering convenience, and account-level sales execution.
• Scale GeneSight in mental health. GeneSight remains a major commercial priority because it addresses a large prescriber base and a broad patient population. The growth agenda appears to rely on clinician education, coverage and reimbursement support, and better execution in the behavioral-health channel.
• Improve reimbursement and revenue-cycle performance. For a company like Myriad, recognized revenue is only part of the story. Public communications have repeatedly highlighted the importance of payer coverage, prior authorization, claims management, denials reduction, and collection efficiency.
• Drive productivity and margin improvement. Myriad has been focused on operating leverage through better lab utilization, cost discipline, and portfolio prioritization. This matters because molecular diagnostics can carry meaningful fixed-cost absorption effects.
• Deepen biopharma and companion-diagnostic relationships. In oncology especially, Myriad’s public strategy points to deeper ties with pharmaceutical companies that need testing support in clinical trials and commercial companion-diagnostic settings.

A cross-cutting initiative behind all of these areas is evidence generation. Myriad’s tests generally win adoption when they have clear clinical utility, guideline support, and reimbursement. That makes publication, clinical validation, and health-economic evidence strategic activities rather than background science work.

3. What Is the Business Model of Myriad Genetics?

Myriad’s business model is primarily a fee-for-service diagnostic testing model. Clinicians order tests for individual patients, specimens are processed in Myriad’s laboratories, and the company bills commercial insurers, government payers, institutions, and in some cases patients. A smaller part of the model comes from biopharma and companion-diagnostic work, which is more project-based and can be lumpier than routine clinical testing.

What customers actually buy: they buy a test result that informs a medical decision. That result may help assess inherited cancer risk, identify whether a tumor is likely to respond to a therapy, estimate recurrence risk, screen a pregnancy, or guide psychiatric medication selection. In many cases, the product is not just raw lab output; it is a clinically interpreted report supported by evidence and reimbursement infrastructure.

Recurring versus one-time revenue: most tests are one-time at the patient level, but the business can be repeat-driven at the account level. OB/GYN practices, cancer centers, psychiatrists, and health systems can generate recurring order flow if Myriad becomes embedded in their workflow. Biopharma revenue is generally project-based rather than recurring in a subscription sense.

Pricing power: Myriad has some pricing power when a test is differentiated, guideline-supported, and reimbursed, but that power is constrained by payer fee schedules, utilization management, prior authorization, and competition from other labs. In this industry, reimbursement strength often matters more than list price.

Why business mix matters: different tests have different average selling prices, reimbursement profiles, evidence burdens, and sales requirements. A favorable mix toward higher-value oncology tests and well-reimbursed branded assays can help margins, while high-volume categories may drive scale but at lower economics per test.

Margin and cash drivers: gross margin depends on lab utilization, automation, cost per sample, and reimbursement realization. Operating margin depends heavily on commercial spending, medical affairs, and R&D intensity. Cash generation is strongly influenced by billing accuracy, payer collections, denials management, and days sales outstanding, not just laboratory throughput.

4. What Products and Services Does Myriad Genetics Sell?

Myriad sells molecular diagnostic tests across oncology, women’s health, and mental health, plus related services for biopharma partners.

• Hereditary cancer testing: Myriad is best known for myRisk, which assesses inherited cancer risk across multiple genes. This remains a foundational product and an important anchor of the oncology franchise.
• Companion diagnostics and precision oncology: myChoice CDx is one of Myriad’s most strategically important oncology products because it can influence therapy selection and tie the company to pharmaceutical workflows. BRACAnalysis CDx is a more established, legacy companion-diagnostic brand. Myriad also offers products such as Precise Tumor and Precise Liquid to broaden its role in tumor profiling.
• Prognostic oncology tests: Prolaris and EndoPredict help inform treatment decisions in prostate and breast cancer settings, respectively.
• Women’s health testing: Foresight Carrier Screen and Prequel Prenatal Screen are important offerings in reproductive carrier screening and non-invasive prenatal screening. These tests are central to Myriad’s women’s health growth agenda.
• Mental health pharmacogenomics: GeneSight helps clinicians understand how genetic factors may influence response to certain psychiatric medications. This has become one of the company’s largest branded franchises.
• Biopharma and clinical services: Myriad also supports pharmaceutical partners with companion-diagnostic development, testing, and related precision-medicine services.

From a business standpoint, GeneSight, myRisk, and the women’s health portfolio appear to be among the company’s most commercially important franchises, while myChoice CDx and related oncology products carry outsized strategic importance because they can strengthen Myriad’s position with biopharma companies and precision-oncology decision pathways.

In legacy-versus-newer terms, BRCA-related hereditary cancer testing is the historical core, while broader multi-gene panels, women’s health testing, mental health pharmacogenomics, and newer oncology profiling offerings represent the diversification strategy.

5. What Are the Key Competitors or Peers of Myriad Genetics?

Myriad competes in several distinct testing categories, so competition is better understood by product area than by a single company-wide rival.

No single competitor perfectly matches Myriad’s full cross-specialty mix. The company’s real competitive challenge is that it faces strong, specialized rivals in almost every one of its growth categories.

6. What Is the Marketing Strategy of Myriad Genetics?

Myriad’s marketing strategy is primarily clinical and channel-based rather than mass-market. The company markets to physicians, genetic counselors, health systems, and biopharma partners far more than it markets directly to the general public. In this type of business, scientific credibility, guideline inclusion, and reimbursement support are usually more important than broad consumer awareness.

Several elements appear central:

• Brand marketing at the test level. Brands such as myRisk, GeneSight, Foresight, and Prequel matter because clinicians often order specific named assays rather than a generic “genetic test.”
• Field marketing and specialist education. Myriad’s sales model depends on in-person and account-based education of specialists such as oncologists, OB/GYNs, psychiatrists, and cancer-center staff.
• Scientific and medical marketing. Conference presence, publications, clinical data, and medical-affairs support are essential because test adoption is evidence-led.
• Market-access support. In diagnostics, affordability and claims support affect conversion. Reimbursement assistance therefore functions as part of the commercial engine, not just back-office administration.
• Digital ordering and workflow tools. Ease of ordering, result access, and practice integration support retention and account growth.

Marketing is an important capability for Myriad, but it is mostly a supporting lever. The deeper differentiators are clinical evidence, payer access, interpretation quality, and account-level commercial execution.

7. What Are the Key Customer Segments of Myriad Genetics?

Myriad serves several distinct customer groups, and each franchise has its own buying logic.

• Oncology specialists and cancer programs: oncologists, surgeons, pathologists, genetic counselors, and cancer centers use Myriad tests for hereditary risk assessment, therapy guidance, and recurrence-related decisions.
• Women’s health providers: OB/GYNs, maternal-fetal medicine specialists, reproductive endocrinologists, and fertility practices use carrier screening and prenatal tests.
• Mental health prescribers: psychiatrists, psychiatric nurse practitioners, and some primary care providers use GeneSight to inform psychotropic medication decisions.
• Health systems and integrated provider organizations: these customers matter because they can influence test formularies, preferred-lab relationships, workflow integration, and volume concentration.
• Biopharma companies: pharmaceutical customers use Myriad for companion diagnostics, testing support, and precision-medicine-related services.
• Payers and government programs: insurers are not always the ordering customer, but they are critical economic stakeholders because coverage and reimbursement strongly shape realized revenue.

Myriad is more diversified than a single-specialty diagnostics company, but it is still highly dependent on a relatively concentrated set of medical specialties and payer decisions in the United States.

8. What Is the Sales Model of Myriad Genetics?

Myriad primarily uses a direct specialist sales model in the United States. Its commercial organization calls on physician offices, hospitals, cancer centers, women’s health providers, and behavioral-health prescribers. The company’s products are generally ordered by clinicians rather than sold through retail channels.

The sales process typically works as follows:

1. A clinician or practice is educated by Myriad’s field team, medical team, or account support staff.
2. The provider orders a test through Myriad’s ordering channels, which may include digital tools and workflow integration.
3. A patient specimen is collected in the care setting and sent to a Myriad laboratory.
4. Myriad processes the test and returns an interpreted result to the ordering clinician.
5. The company then manages billing, reimbursement, and support activities.

For biopharma customers, the go-to-market model is more enterprise-oriented, relying on business-development and scientific collaboration rather than a traditional physician-detail model. Internationally, Myriad also uses partner channels in selected markets.

This channel structure matters strategically. A direct commercial model gives Myriad more control over physician education and customer intimacy, but it also adds fixed cost. That makes salesforce productivity and territory design especially important.

9. In What Geographies Does Myriad Genetics Operate?

Myriad’s business is concentrated in the United States, which is the company’s main market for commercial testing, payer relationships, and field sales activity. Its international business is smaller and appears to be more selective, focusing on markets and use cases where its branded assays or companion-diagnostic capabilities can travel effectively.

According to recent company filings, Myriad’s footprint has included facilities in Salt Lake City, Utah, as well as additional locations such as South San Francisco, California, Mason, Ohio, and Munich, Germany. Those sites reflect the company’s history of acquisitions and multi-franchise laboratory and commercial operations.

From a customer perspective, the company serves clinicians and partners in the United States most heavily, with a more limited direct or partner-led presence in parts of Europe and other selected international markets. For investors and strategic planners, the key point is that Myriad is geographically present in more than one country, but economically it remains primarily a U.S.-focused diagnostics company.

10. Who Are the Owners of Myriad Genetics?

Myriad Genetics is a publicly traded company. Ownership is broadly dispersed among institutional investors rather than concentrated in a single controlling shareholder. Based on recent proxy materials and public beneficial-ownership filings around the 2024 period, large institutional holders included firms such as BlackRock and The Vanguard Group. No controlling stake was disclosed.

11. How Is Myriad Genetics Organized?

As of FY2024, Myriad reported one reportable segment. That is the formal reporting view. In practical management terms, however, the business is easier to understand through its major clinical franchises: Oncology, Women’s Health, and Mental Health, plus associated biopharma and companion-diagnostic activities.

The organization also relies on shared capabilities across the portfolio, including laboratory operations, bioinformatics, medical affairs, reimbursement and market access, sales, finance, legal and regulatory, and corporate functions. This shared-services model matters because many capabilities in molecular diagnostics, such as quality systems and claims management, can support multiple test categories at once.

Legally, Myriad Genetics, Inc. sits above subsidiaries and acquired entities that have contributed brands and capabilities over time. Managerially, the company appears organized around product-line accountability layered onto shared scientific and commercial infrastructure.

12. How Does Myriad Genetics Operate?

On a day-to-day basis, Myriad operates as a specialized diagnostics platform. The value-creation process runs through a sequence of clinical, laboratory, interpretation, and reimbursement steps.

1. Demand generation and ordering: clinicians decide to use a Myriad test, often after interacting with the company’s sales force, medical team, or digital ordering tools.
2. Specimen collection and logistics: a blood, saliva, tissue, or other sample is collected and shipped to Myriad’s laboratory infrastructure.
3. Laboratory processing: Myriad performs the underlying molecular analysis using its testing platforms, workflows, and quality systems.
4. Bioinformatics and interpretation: raw results are translated into a clinically meaningful report using interpretation rules, evidence, and internal data resources.
5. Report delivery and support: the result goes back to the clinician, often supported by interpretive or reimbursement assistance.
6. Billing and collections: Myriad bills payers, institutions, and patients, then manages claims, denials, appeals, and collections.

The operational complexities are substantial. Myriad must manage sample integrity, turnaround time, assay quality, regulatory compliance, data interpretation, customer service, and reimbursement at the same time. In diagnostics, operational excellence is not just about running the lab efficiently; it is also about getting paid efficiently and keeping clinicians confident in the result.

13. What Are the Growth Opportunities for Myriad Genetics?

The most plausible growth opportunities for Myriad are closely tied to areas the company already emphasizes publicly.

• Broader hereditary cancer testing adoption. Clinical guidelines and awareness have expanded the addressable population for hereditary cancer risk assessment. Myriad can benefit if it captures more testing earlier in the patient pathway.
• Women’s health penetration. Carrier screening and prenatal screening remain large markets, and Myriad has room to deepen penetration with OB/GYN practices, fertility providers, and health systems.
• Precision oncology and companion diagnostics. This is one of the most strategically important opportunities because it can combine clinical testing revenue with biopharma relationships and higher-value decision support.
• Mental health expansion through GeneSight. The mental health market is large, and GeneSight gives Myriad exposure to a broader prescriber base than many oncology-focused diagnostics companies have.
• International and partner-led expansion. Myriad’s international base is smaller than its U.S. business, so selective expansion can add growth without requiring the same level of fixed commercial investment everywhere.
• Better reimbursement realization and operating leverage. Not all growth has to come from higher test volumes. Improving payer coverage, claims realization, and lab productivity can increase earnings power materially.

The main constraints are equally clear: payer scrutiny, competitive pricing pressure, the need for ongoing clinical evidence, uneven physician adoption, and the operational difficulty of scaling multiple test categories simultaneously.

14. What Is the History of Myriad Genetics?

Myriad was founded in 1991 by scientists and entrepreneurs including Mark Skolnick and Peter Meldrum, with roots in the University of Utah research community. The company initially became well known for gene discovery and hereditary cancer testing.

• 1995: Myriad became a public company, giving it capital to expand its diagnostics and genomics activities.
• Late 1990s to early 2010s: the company built a powerful position around BRCA-related hereditary cancer testing and became closely associated with the commercialization of BRCA testing in the United States.
• 2013: the U.S. Supreme Court’s decision in Association for Molecular Pathology v. Myriad Genetics invalidated key patent claims on naturally occurring DNA sequences. That was a watershed event in the company’s history because it opened the hereditary testing market to more competition.
• 2016: Myriad acquired Assurex Health, adding GeneSight and creating a major entry into mental health pharmacogenomics.
• 2016: it also acquired Sividon Diagnostics, which added EndoPredict and strengthened its oncology portfolio in Europe.
• 2018: the acquisition of Counsyl expanded Myriad meaningfully in reproductive carrier screening and prenatal testing.
• 2021: Myriad acquired Gateway Genomics, reflecting interest in adjacent reproductive and consumer-oriented testing opportunities.

The broad historical arc is clear: Myriad evolved from a company identified with a narrow hereditary cancer franchise into a more diversified precision-diagnostics company with multiple branded test lines. The major strategic question since the gene-patent era has been how effectively it can convert that broader portfolio into durable growth and better economics.

15. What Are the Key Brands Owned by Myriad Genetics?

Branding matters at Myriad because physicians often order specific named tests rather than thinking of the company as a generic laboratory. In other words, the brand architecture sits at the assay level.

For Myriad, strong product branding is not cosmetic. It supports physician recall, clinical positioning, and reimbursement conversations in categories where multiple labs may offer overlapping tests.

16. What Is the Technology Strategy of Myriad Genetics?

Technology is central to Myriad’s competitiveness, but mostly as an internal enabler of differentiated diagnostics rather than as a software product sold on its own. The company’s technology strategy appears to rest on several layers.

• Testing platforms and assay design: Myriad needs robust laboratory technologies for sequencing, genotyping, sample processing, and assay performance across multiple disease areas.
• Bioinformatics and interpretation: one of the most important technology assets in genetic testing is the ability to classify and interpret variants consistently and at scale. Myriad’s long operating history gives it a meaningful interpretation and data-management advantage if that information is used well.
• Workflow and digital infrastructure: ordering systems, electronic result delivery, and customer-service tools help make tests easier to adopt and harder to displace.
• Regulated companion-diagnostic capabilities: in oncology, technology is also tied to the ability to support biopharma partners, manage assay validation, and operate in more formal regulatory settings.
• Laboratory automation and productivity: automation supports cost per test, turnaround time, and quality consistency, all of which matter to margins and customer experience.

The key strategic distinction is that Myriad uses technology to improve diagnostic accuracy, usability, and economics. It is not primarily a platform-software company; it is a diagnostics company whose technology stack must make its branded tests more clinically valuable and operationally scalable.

17. What Is the R&D Strategy of Myriad Genetics?

Myriad’s R&D strategy is best understood as applied diagnostics innovation rather than basic scientific research. The company invests in assay development, clinical validation, evidence generation, and expansion of existing tests into broader clinical use.

Several elements appear important:

• New test and assay development: designing and validating tests that address meaningful clinical questions in oncology, women’s health, and mental health.
• Clinical utility evidence: publishing data and building evidence that physicians and payers can use to justify adoption and reimbursement.
• Companion-diagnostic development: working with pharmaceutical companies to align tests with targeted therapies is a particularly strategic form of R&D because it can produce durable commercial relationships.
• Interpretation improvements: refining variant classification and report quality is an ongoing scientific activity, not a one-time database exercise.
• Menu expansion within existing channels: Myriad can often create leverage by developing adjacent assays that fit the same customer relationships and laboratory infrastructure.

This matters because diagnostics R&D must do more than prove scientific feasibility. It has to produce a product that is clinically accepted, operationally scalable, and reimbursable. For Myriad, that makes medical affairs and payer-facing evidence nearly as important as the lab science itself.

18. What Is the Finance Strategy of Myriad Genetics?

As of FY2024, Myriad’s finance strategy appeared geared toward balancing portfolio investment with margin improvement and cash discipline. The company is not a mature cash-return story; it is still in a phase where execution, profitability, and capital allocation matter more than dividend signaling.

• Reinvest behind core growth franchises. Women’s health, GeneSight, and precision oncology require continued commercial and evidence investment.
• Improve operating leverage. Laboratory utilization, cost control, and productivity are important because the business carries significant fixed infrastructure.
• Strengthen reimbursement and collections. Finance strategy in diagnostics is tightly linked to revenue-cycle management, not just budgeting and treasury.
• Be selective on capital allocation. Myriad has historically used acquisitions to add capabilities, but the more recent emphasis appears to be on getting better returns from the existing portfolio rather than pursuing diversification for its own sake.
• Support strategic flexibility. Maintaining liquidity and balance-sheet flexibility matters because diagnostics markets can shift with regulation, reimbursement, and product cycles.

In practical terms, Myriad’s finance function is strategic because it sits at the intersection of pricing realization, working capital, investment pacing, and portfolio choices.

19. What Major Acquisitions Has Myriad Genetics Made?

Acquisitions have played an important role in Myriad’s evolution from a hereditary-cancer specialist into a broader precision-diagnostics company. The pattern has generally been capability- and category-expanding rather than purely scale-driven.

Myriad has also reshaped the portfolio through divestitures and prioritization moves, which suggests that its M&A logic is not simply to accumulate assets. The more recent strategic emphasis appears to be on integrating what it has bought and improving execution across the portfolio.

20. How Companies Like Myriad Genetics Leverage Independent Consultants through Umbrex

For a company like Myriad, consultants are most useful when management needs targeted expertise on a high-stakes issue without paying for a large multi-layer consulting team. Umbrex has grown a global community of over 8,000 independent management consultants based in more than 50 countries. These consultants are alumni of McKinsey, Bain, BCG, and other top firms. Companies like Myriad use Umbrex when they need strategy, operations, organization, marketing, sales, finance, technology, ERP, or AI expertise in a flexible model tied to a specific initiative.

Representative project examples for a company such as Myriad include:

• Oncology portfolio growth strategy: assess where to place commercial and R&D emphasis across hereditary cancer, HRD testing, prognostics, and newer tumor-profiling products.
• Women’s health channel expansion: redesign go-to-market coverage for OB/GYN, fertility, and maternal-fetal medicine accounts to accelerate adoption of Foresight and Prequel.
• GeneSight commercial productivity: optimize territory design, prescriber targeting, message sequencing, and account-based selling in behavioral health.
• Reimbursement and revenue-cycle transformation: improve prior authorization workflows, denial management, payer strategy, and collections performance.
• Laboratory operations improvement: reduce turnaround times, improve sample-flow management, and identify automation opportunities across multi-test lab operations.
• Companion-diagnostic partnership strategy: prioritize pharmaceutical partnership opportunities, define deal economics, and shape market-entry plans for new oncology-linked assays.
• International partner strategy: evaluate which tests travel best outside the United States, which markets merit direct investment, and where distributor or partner models are more sensible.
• M&A screening and integration: assess tuck-in diagnostic assets, build synergy cases, and support integration of acquired commercial teams, brands, or laboratory platforms.
• Technology and workflow roadmap: redesign digital ordering, customer service, CRM, and physician workflow integration to improve retention and sales efficiency.
• AI opportunity assessment: identify where AI can realistically improve variant interpretation support, customer operations, reimbursement workflows, forecasting, or internal productivity without disrupting regulated clinical processes.